<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912219</url>
  </required_header>
  <id_info>
    <org_study_id>Cooper-Microneedling</org_study_id>
    <nct_id>NCT04912219</nct_id>
  </id_info>
  <brief_title>Microneedling for Dermatoporosis</brief_title>
  <official_title>Microneedling for Dermatoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cooper Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cooper Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that a series of treatments with a microneedling protocol will lead to&#xD;
      increased dermal thickness as measured by biopsy, ultrasound, and skin calipometry; an&#xD;
      improvement in dermatology-related quality of life; and a reduction in the number of&#xD;
      ecchymoses and skin tears, of the research subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dermatoporosis is a common condition, affecting between 30-37% of the population greater than&#xD;
      age 65. It may lead to easy bruising, skin tearing, infections, and scars.&#xD;
&#xD;
      The pathogenesis of dermatoporosis involves decreased expression of collagen I, collagen III,&#xD;
      and collagen IV; upregulation of matrix metalloproteinases 1, 2, and 3; downregulation of&#xD;
      issue inhibitor of matrix metalloprotein I; loss of elastic tissue; defective fibroblast&#xD;
      synthesis of collagen; and loss of hyaluronic acid.&#xD;
&#xD;
      Microneedling, also known as percutaneous collagen induction therapy, is a safe, established&#xD;
      technique for treatment of acne scarring, rhytides, cellulite, and improvement of skin&#xD;
      texture.&#xD;
&#xD;
      Microneedling has been demonstrated to stimulate growth factor release and increase dermal&#xD;
      collagen and elastic fibers. It is effective in improving facial laxity, acne scarring, and&#xD;
      facial rhytides.&#xD;
&#xD;
      Microneedling is safe and well tolerated. Expected adverse events include bleeding and oozing&#xD;
      of the skin surface, redness, swelling, and peeling. Reported complications include&#xD;
      post-inflammatory pigmentary changes, granulomatous reactions and systemic hypersensitivity&#xD;
      reactions.&#xD;
&#xD;
      References:&#xD;
&#xD;
        1. Wollina U, Lotti T, Vojvotic A, Nowak A. Dermatoporosis - The Chronic Cutaneous&#xD;
           Fragility Syndrome. Open Access Maced J Med Sci. 2019;7(18):3046-3049.&#xD;
&#xD;
        2. Dyer JM, Miller RA. Chronic Skin Fragility of Aging: Current Concepts in the&#xD;
           Pathogenesis, Recognition, and Management of Dermatoporosis. J Clin Aesthet Dermatol.&#xD;
           2018;11(1):13-18.&#xD;
&#xD;
        3. McCrudden MT, McAlister E, Courtenay AJ, Gonzalez-Va ÃÅzquez P, Singh TR, Donnelly RF&#xD;
           Microneedle applications in improving skin appearance. Exp Dermatol 2015;24(8):561-566.&#xD;
&#xD;
        4. Doddaballapur S. Microneedling with dermaroller. J Cutan AesthetSurg 2009;2:110-1.10&#xD;
&#xD;
        5. Aust MC, Reimers K, Kaplan HM, Stahl F, et al. Percutaneous&#xD;
           collageninduction-regeneration in place of cicatrisation? J Plast Reconstr Aesthet Surg&#xD;
           2011;64:97-107.11.&#xD;
&#xD;
        6. Schwarz M, Laaff H. A prospective controlled assessment of microneedling with the&#xD;
           Dermaroller device. Plast Reconstr Surg 2011;127:146e-148e.14.&#xD;
&#xD;
        7. Hou A, Cohen B, Haimovic A, Elbuluk N. Microneedling: A Comprehensive Review. Dermatol&#xD;
           Surg. 2017 Mar;43(3):321-339&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin thickness</measure>
    <time_frame>one year</time_frame>
    <description>Thickness of skin as measured by skin biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin thickness ultrasound</measure>
    <time_frame>6 months</time_frame>
    <description>Thickness of skin as measured by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology-related quality of life</measure>
    <time_frame>six months and one year</time_frame>
    <description>Dermatology quality of life index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ecchymoses</measure>
    <time_frame>six months and one year</time_frame>
    <description>Number of ecchymoses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Solar Purpura</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedling</intervention_name>
    <description>Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.&#xD;
Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.&#xD;
Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.&#xD;
This will be repeated for a total of four treatments one month apart</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients will be eligible for inclusion in the study if they are age 60 or older and&#xD;
             have dermatoporosis of the dorsal forearms as defined by any or all of the following:&#xD;
             white pseudoscars, senile purpura, or skin atrophy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria: Patients with liver disease, heart disease, active infection,&#xD;
             keloid predisposition, immunosuppression, genetic predisposition to poor wound&#xD;
             healing, active cancer in the treatment area, bleeding disorders, pregnancy or&#xD;
             nursing, taking the medication isotretinoin, with open wounds, sores or irritated skin&#xD;
             in the treatment area, allergy to stainless steel or anesthetics, or skin phototype 4&#xD;
             or greater will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M McLarney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard M McLarney, MD</last_name>
    <phone>956-802-0558</phone>
    <email>matt.mclarney@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naomi Lawrence, MD</last_name>
    <phone>856-596-3040</phone>
    <email>lawrence-naomi@cooperhealth.edu</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

